Paclitaxel Drug-Coated Balloon (Optilume®) for Bladder Neck Stenosis and Vesicourethral Anastomotic Stenosis: A Narrative Review
Medicina · 06.05.2026 · 62 (5) · 898
DOI: 10.3390/medicina62050898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, online erschienen am 06.05.2026. Verfasst von Tomasz Ufniarski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Urology Clinic, University Clinical Centre, 80-952 Gdańsk, Poland. Hauptthemen laut MEDLINE: Paclitaxel, Urinary Bladder Neck Obstruction, Urethral Stricture. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Bladder neck stenosis (BNS) and vesicourethral anastomotic stenosis (VUAS) are challenging complications following prostate surgery and radiation therapy, with recurrence rates reaching 30–60% after conventional endoscopic management. The Optilume® paclitaxel drug-coated balloon (DCB) has emerged as a novel minimally invasive treatment combining mechanical dilation with local anti-fibrotic drug delivery. This narrative review synthesizes current evidence on Optilume DCB specifically for BNS and VUAS. Materials and Methods: A comprehensive literature search identified eight relevant publications (2024–2026), including randomized controlled trials, prospective and retrospective cohort studies, and case series addressing Optilume DCB for posterior urethral stenoses.
Results
Across the reviewed studies, freedom from reintervention for BNS ranged from 77.5% to 100% at 12 months, while VUAS outcomes were more variable (40–81%). A comparative study of 141 patients demonstrated significantly improved recurrence-free survival with DCB versus standard endoscopic treatment (HR 0.40, p = 0.021). Radiation-induced posterior urethral stenosis showed 81.1% freedom from repeat intervention. Complications were predominantly minor (Clavien-Dindo grade I), with no de novo incontinence attributable to the device.
Conclusions
Optilume DCB represents a promising minimally invasive option for BNS and VUAS, particularly in patients with recurrent disease or those unsuitable for reconstructive surgery. BNS appears to respond more favorably than VUAS, likely reflecting distinct pathophysiological mechanisms. Prior radiation therapy remains a negative prognostic factor. Prospective randomized trials with longer follow-up are needed to define the role of DCB in posterior urethral stenosis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Clinic, University Clinical Centre, 80-952 Gdańsk, Poland.
- Department of Urology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
- Department of Pharmaceutical Technology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
ORCID-Profile: Tomasz Ufniarski, Mikołaj Frankiewicz, Maja Frankiewicz, Marcin Matuszewski
Zitieren
APA
Ufniarski, T., Frankiewicz, M., Frankiewicz, M., & Matuszewski, M. (2026). Paclitaxel Drug-Coated Balloon (Optilume®) for Bladder Neck Stenosis and Vesicourethral Anastomotic Stenosis: A Narrative Review. Medicina, 62(5), 898. https://doi.org/10.3390/medicina62050898
Vancouver
Ufniarski T, Frankiewicz M, Frankiewicz M, Matuszewski M. Paclitaxel Drug-Coated Balloon (Optilume®) for Bladder Neck Stenosis and Vesicourethral Anastomotic Stenosis: A Narrative Review. Medicina. 2026;62(5):898. doi:10.3390/medicina62050898
BibTeX
@article{Ufniarski2026,
author = {Ufniarski, Tomasz and Frankiewicz, Mikołaj and Frankiewicz, Maja and Matuszewski, Marcin},
title = {Paclitaxel Drug-Coated Balloon (Optilume®) for Bladder Neck Stenosis and Vesicourethral Anastomotic Stenosis: A Narrative Review},
journal = {Medicina},
year = {2026},
volume = {62},
number = {5},
pages = {898},
doi = {10.3390/medicina62050898}
}
EUVIMED